Netscientific portfolio company nets positive report

Healthcare intellectual property commercialisation group Netscientific has today highlighted a positive report displaying the potential of Vortex Technology in cancer treatment.

Research into the technology, developed by Netscientific’s portfolio company Vortex Biosciences, has yielded positive results according to the report published by Nature Scientific Reports.

Francois Martelet, chairman of Vortex Biosciences, said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients."

The news comes just weeks after Netscientific hailed the progress of its portfolio companies Glycotest, ProAxsis, Wanda, PDS and the aforementioned Vortex Biosciences.

Glycotest, a liver diagnostics company based in the US, is planning to move forward with commercialization and secure its first sale while Wanda and PDS will hold financing events in 2018.

ProAxis expanded its contract with Diagenics and is targeting £1m in revenue in 2018 with the possibility of becoming free cash flow positive over the year.

“We are pleased to note that all of our core portfolio companies continue to advance their commercial operations and are well positioned for continued momentum as we move into 2018,” Martelet said.